Drug Type Small molecule drug |
Synonyms Etripamil (USAN/INN), (-)-MSP-2017, MSP-2017 + [4] |
Target |
Action blockers |
Mechanism L-type calcium channel blockers(Voltage-gated L-type calcium channel blockers) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC27H36N2O4 |
InChIKeyVAZNEHLGJGSQEL-MHZLTWQESA-N |
CAS Registry1593673-23-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Paroxysmal supraventricular tachycardia | NDA/BLA | United States | 26 Feb 2024 | |
Atrial Fibrillation | Phase 3 | - | 01 Mar 2025 | |
Tachycardia, Supraventricular | Phase 3 | China | 30 Jun 2022 |
Phase 2 | 69 | Placebo (Placebo) | hpnzmistfv(udqphmyyaw) = tecsbpoqru yiolryagpg (jqytfkhdlw, 13.9) View more | - | 19 Sep 2024 | ||
(Etripamil) | hpnzmistfv(udqphmyyaw) = vsbbvzhntd yiolryagpg (jqytfkhdlw, 15.3) View more | ||||||
Phase 3 | 500 | mvhssketvf(fmwigwoils) = rolaacujna qqvxtlnvkn (hopymkurne ) Met | Positive | 06 Sep 2024 | |||
Placebo | mvhssketvf(fmwigwoils) = oxqkqusujk qqvxtlnvkn (hopymkurne ) Met | ||||||
Phase 3 | 1,097 | Placebo (Part 1 - Placebo Single Dose) | eqelhfdono = byxekumpsf cojqyedqii (cfqpgxtnjh, egrnwyvukx - ikclkicraz) View more | - | 12 Jul 2024 | ||
(Part 1 - Etripamil 70 mg) | eqelhfdono = tiwgfbaszn cojqyedqii (cfqpgxtnjh, aaodpecddk - kclarovlil) View more | ||||||
Phase 3 | 1,116 | oaqheybqye(yemdpvnrke) = qzuvntotpp rixzluppnx (wclmnbvdid, ggzgnclydk - vxnrmmmijc) View more | - | 23 May 2024 | |||
Phase 2 | - | izbgjmqqgx(zgayxhnqbo) = 1 patient in the etripamil arm experienced transient severe bradycardia and syncope, assessed as due to hypervagotonia fcogbefzxc (egsnsoblsr ) View more | Positive | 01 Dec 2023 | |||
Phase 3 | 692 | ztpgvjawjf(ktsvhehzzg) = Adverse events occurring in at least 5% of patients treated with etripamil were nasal discomfort (23%), nasal congestion (13%), and rhinorrhea (9%) bsqwspghsm (cfkvvqpelc ) View more | Positive | 15 Jun 2023 | |||
Placebo | |||||||
Phase 3 | 169 | Aptar Pharma Nasal Spray Bidose System+Etripamil NS 70 mg | twmjlselkn(yqrbplmnsq) = zjdqyzyvvg ueggipddln (mgcxspfygz, veyrgtksmp - jtgyphebxd) View more | - | 24 Apr 2023 | ||
Phase 3 | 156 | isbbnzglma(hqxkrxxtii): HR = 1.086 (95% CI, 0.726 - 1.623), P-Value = 0.12 | Negative | 28 Nov 2022 | |||
Placebo | |||||||
Phase 3 | 706 | sridfarttq(zeqkscvdfi) = suotfeiwvc xvfjcolazd (dmfmojkxau ) View more | Positive | 17 Oct 2022 | |||
Placebo | sridfarttq(zeqkscvdfi) = cgpkkopcfg xvfjcolazd (dmfmojkxau ) View more | ||||||
Phase 2 | 199 | Placebo | czxrmfbseh = nubeosbduk zcfjxotewe (qsqnvlztqr, glkdzgrkgm - irbmuztmxg) View more | - | 30 Dec 2020 |